Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987764 | 0.87 | ADORA2A (0.41) | HSP90AB1ADORA2AFGFR1ADORA2B | |
| SCHEMBL22979975 | 0.86 | HSP90AB1 (0.42) | HSP90AB1ADORA2AADORA1ADORA3 | |
| SCHEMBL22988090 | 0.86 | HSP90AB1 (0.45) | HSP90AB1ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL22987424 | 0.85 | ADORA3 (0.40) | HSP90AB1ADORA2AADORA1ADORA3 | |
| SCHEMBL22988018 | 0.85 | ADORA2A (0.42) | HSP90AB1ADORA2AFGFR1ADORA2B | |
| SCHEMBL22987463 | 0.84 | ADORA3 (0.39) | ADORA2AADORA1MAP4K1ADORA3 | |
| SCHEMBL22979176 | 0.84 | ADORA3 (0.39) | ADORA2AADORA1ADORA3 | |
| SCHEMBL22987639 | 0.83 | ADORA3 (0.38) | ADORA2AADORA1ADORA3 | |
| SCHEMBL22978982 | 0.83 | ADORA3 (0.38) | ADORA2AADORA1ADORA3 | |
| SCHEMBL29646424 | 0.83 | ADORA3 (0.38) | ADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | HSP90AB1 2893/4885ADORA2A 103/4885ADORA1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.